(Q42689640)

4 November 2017

title

In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment (English)

1 reference

4 November 2017

0 references

1 reference

7

Hans-Peter Tony

1 reference

4 November 2017

5

Hermann Einsele

1 reference

4 November 2017

Petra Roll

1

1 reference

4 November 2017

Khalid Muhammad

2

1 reference

4 November 2017

Mathias Schumann

3

1 reference

4 November 2017

Stefan Kleinert

4

1 reference

4 November 2017

Thomas Dörner

6

1 reference

4 November 2017

language of work or name

1 reference

1 May 2011

1 reference

4 November 2017

number of pages

10

1 reference

based on heuristic

inferred from page(s)

published in

Arthritis & Rheumatology

1 reference

4 November 2017

volume

63

1 reference

4 November 2017

issue

5

1 reference

4 November 2017

page(s)

1255-1264

1 reference

Interleukin-6 as a key player in systemic inflammation and joint destruction.

4 November 2017

cites work

1 reference

Interleukin-6 and rheumatic diseases

21 January 2018

1 reference

Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer

21 January 2018

1 reference

The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells

21 January 2018

1 reference

Directing transition from innate to acquired immunity: defining a role for IL-6.

21 January 2018

1 reference

IL-6 produced by immune complex-activated follicular dendritic cells promotes germinal center reactions, IgG responses and somatic hypermutation

21 January 2018

1 reference

Interleukin 6 influences germinal center development and antibody production via a contribution of C3 complement component

21 January 2018

1 reference

The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells

21 January 2018

1 reference

Roles of B cells in rheumatoid arthritis

21 January 2018

1 reference

Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity

21 January 2018

1 reference

Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti-CD20 therapy: the B-cell roadblock hypothesis

21 January 2018

1 reference

Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor

21 January 2018

1 reference

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

21 January 2018

1 reference

21 January 2018

1 reference

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

21 January 2018

1 reference

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

21 January 2018

1 reference

Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals.

21 January 2018

1 reference

Humoral immunity and long-lived plasma cells

21 January 2018

1 reference

Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease

21 January 2018

1 reference

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease

21 January 2018

1 reference

Rationale for interleukin-6 blockade in systemic lupus erythematosus

21 January 2018

1 reference

Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus

21 January 2018

1 reference

Disturbances in B- and T-cell homeostasis in rheumatoid arthritis: suggested relationships with antigen-driven immune responses.

21 January 2018

1 reference

Current aspects of anti-CD20 therapy in rheumatoid arthritis

21 January 2018

1 reference

Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor

21 January 2018

1 reference

Alterations on peripheral blood B-cell subpopulations in very early arthritis patients.

21 January 2018

1 reference

Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis

21 January 2018

1 reference

Role of the spleen in peripheral memory B-cell homeostasis in patients with autoimmune thrombocytopenia purpura

21 January 2018

1 reference

Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen

21 January 2018

1 reference

Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment

21 January 2018

1 reference

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

21 January 2018

1 reference

In vitro regulation of B cell differentiation by interleukin-6 and soluble CD23 in systemic lupus erythematosus B cell subpopulations and antigen-induced normal B cells

21 January 2018

1 reference

The role of interleukin-6 in mucosal IgA antibody responses in vivo

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ART.30242

1 reference

release_rzjz5ymx3facvg6e64pdtqlvvi

4 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rzjz5ymx3facvg6e64pdtqlvvi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference